Nelson, 1997 - Google Patents
Clinical ProfileNelson, 1997
- Document ID
- 4026766043253327718
- Author
- Nelson D
- Publication year
- Publication venue
- Red Blood Cell Substitutes: Basic Principles and Clinical Applications: Basic Principles and Clinical Applications
External Links
Snippet
Since antiquity, blood has had a special significance to humankind. For exam-ple, blood oaths between blood brothers represented the most earnest commit-ment to work together to achieve a particular goal. Blood feuds struck at the hearts of both sides of a family or clan …
- 210000004369 blood 0 abstract description 116
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Remy et al. | Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions | |
| US8129338B2 (en) | Nitric oxide-blocked cross-linked tetrameric hemoglobin | |
| ES2032802T5 (en) | SUCEDANEO OF EXTRAPUR SEMISINTETIC BLOOD. | |
| US5084558A (en) | Extra pure semi-synthetic blood substitute | |
| US5296465A (en) | Ultra pure hemoglobin solutions and blood-substitutes | |
| Palmer et al. | Blood substitutes | |
| Winslow | αα–Crosslinked Hemoglobin: Was Failure Predicted by Preclinical Testing? | |
| US7494974B2 (en) | Carboxymethylated cross-linked tetrameric hemoglobin | |
| SG182237A1 (en) | A method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereoff | |
| Chang | Blood substitutes based on modified hemoglobin prepared by encapsulation or crosslinking: An overview | |
| Ketcham et al. | Hemoglobin-based oxygen carriers: development and clinical potential | |
| Lieberthal et al. | O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin | |
| US6894150B1 (en) | Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin | |
| Levy | The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss | |
| US5854210A (en) | Use of cross-linked hemoglobin in treating subarachnoid hemorrhage | |
| Simoni et al. | An improved blood substitute: In vivo evaluation of its renal effects | |
| Seeger et al. | Pulmonary vasoconstrictor response to soluble fibrin in isolated lungs: possible role of thromboxane generation. | |
| Nelson | Clinical Profile | |
| Nelson | Baxter Healthcare Corporation, Round Lake, Illinois | |
| RU2145873C1 (en) | Method of commercial-scale purification of hemoglobin | |
| Rudolph | * HemAssist™: Development and Clinical Profile | |
| Scatena et al. | O-raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier | |
| Yan et al. | Hydroxyethyl Starch–Bovine Hemoglobin Conjugate as an Effective Oxygen Carrier with the Ability to Expand Plasma | |
| Awasthi | Pharmaceutical aspects of hemoglobin-based oxygen carriers | |
| Standl | Artificial oxygen carriers as red blood cell substitutes–perfluorocarbons and cell-free hemoglobin |